The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting resilient demand across the healthcare and technology sectors, Quest Diagnostics and ServiceNow have both raised their full-year financial forecasts. According to reports, Quest Diagnostics increased its annual profit outlook after second-quarter results surpassed analyst estimates, driven by a surge in demand for routine diagnostic testing. Similarly, ServiceNow raised its full-year subscription revenue forecast as rapid adoption of AI products bolstered its financial performance.
These positive results reinforce confidence in key growth areas, with Quest Diagnostics benefiting from a recovery in routine medical testing volumes and ServiceNow seeing increased demand for generative AI software solutions. Per market data, ServiceNow (NOW) shares closed at $95.46 (close July 22, 2026), with the stock trading between a session low of $94.74 and a high of $101.16.
Investors should watch for the sustainability of this growth amid broader macroeconomic shifts, as the NOW stock price remains at its recent levels following the announcement. Looking at the economic calendar, there are no direct upcoming catalysts for these instruments in the next seven days, leaving the market to focus on how these updated guidances impact overall sector sentiment.